Efficacy and safety of a novel CD19, CD22 dual-targeted fully human loop bi-CAR-T for the treatment of relapsed/refractory B cell non-Hodgkin lymphoma.
Saved in:
| Title: | Efficacy and safety of a novel CD19, CD22 dual-targeted fully human loop bi-CAR-T for the treatment of relapsed/refractory B cell non-Hodgkin lymphoma. |
|---|---|
| Authors: | Wang, Hanyu1 (AUTHOR), Wang, Gaoxiang1 (AUTHOR), Li, Tongjuan1 (AUTHOR), Zhang, Peiling1 (AUTHOR), Mao, Zekai1 (AUTHOR), Luo, Hui1 (AUTHOR), Zhu, Xiaojian1 (AUTHOR), Li, Dengju1 (AUTHOR), Zhou, Jianfeng1 (AUTHOR), Zhou, Xiaoxi1 (AUTHOR) cello316@tjh.tjmu.edu.cn, Huang, Liang2,3 (AUTHOR) huangliang@ihcams.ac.cn |
| Source: | Journal of Translational Medicine. 6/5/2025, Vol. 23 Issue 1, p1-13. 13p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 14795876 |
|---|---|
| DOI: | 10.1186/s12967-025-06567-3 |
